SNTI · Senti Biosciences, Inc.

Senti Bio reported first quarter 2026 financial results that reflect continued operational streamlining. Net loss narrowed significantly to $4.2 million from $14.1 million in the prior year period, primarily due to a $6.9 million non-recurring gain on lease modification and lower operating expenses. Research and development expenses decreased to $5.3 million from $9.3 million, and general and administrative expenses fell to $6.2 million from $7.1 million, both driven by reduced external services and supplies costs. Cash burn from operations improved to $7.5 million from $14.1 million year-over-year. Cash and equivalents stood at $8.9 million as of March 31, 2026, down from $16.4 million at year-end 2025. The company also secured a strategic financing agreement for up to $40 million in senior secured convertible notes, with an initial $10 million tranche expected to close in May 2026, providing additional runway. On the clinical front, Senti Bio announced positive FDA feedback from a Type B RMAT meeting supporting a single-arm pivotal trial for SENTI-202 in relapsed/refractory AML, a potential registrational path. The company also identified a Donor X phenotype that correlates with improved efficacy—50% composite CR rate versus 12.5% without—and will use this donor selection criterion in all future manufacturing. Updated Phase 1 data showed durable MRD-negative complete remissions, with all CR/CRh responders from the prior data cut maintaining remission with up to 21+ months follow-up. Management believes these developments position SENTI-202 for later-stage development and potential registration.